N/A
N=306
DreamKit Diagnostic Validation
Sleep Apnea, Obstructive · Sleep Apnea, Central
Bottom Line
View on ClinicalTrials.gov: NCT04671342 ↗Enrolled (actual)
306
Serious AEs
0.0%
Results posted
Jan 2023
Primary outcome: Primary: Intraclass Correlation Coefficient (ICC) of the Apnea Hypopnea Index — 0.964 intraclass correlation coefficient (ICC)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- DreamKit (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Philips Clinical & Medical Affairs Global
- Primary completion
- Dec 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intraclass Correlation Coefficient (ICC) of the Apnea Hypopnea Index |
0.964 | — |
| SECONDARY Intraclass Correlation Coefficient (ICC) of the Central Apnea Index |
0.731 | — |
Summary
This study has been developed in order to demonstrate diagnostic efficacy of the DreamKit device against polysomnography.
Eligibility Criteria
Inclusion Criteria
- Aged ≥18 years;
- Fluent in English;
- Able to provide informed consent.
Exclusion Criteria
- Self-reported habitual sleep duration of <4 hours/night on average ("How many hours sleep do you usually get per night?");
- Circadian phase disorder, shift work, or any other issue/condition that would, in the opinion of the site investigator, reduce the likelihood of obtaining at least four hours of sleep during the overnight study;
- History of allergic reactions to medical adhesives;
- Skin rash or other dermatological condition that would impact correct placement of the DreamKit device and/or PSG sensors, and/or would be exacerbated by the presence of the device or sensors;
- Presence of a pacemaker;
- Severe medical condition (controlled or uncontrolled) that would impede data collection in the opinion of the site investigator, including the requirement for oxygen therapy;
- [for those currently using overnight therapy]: Unwilling to withdraw from overnight therapy for a single night and/or clinically unsuitable to withdraw from overnight therapy in the opinion of the site investigator, with overnight therapy including but not limited to any form of PAP or ventilation, oral device including mandibular advancement devices or mouthguard for bruxism, nasal dilator strips, and/or positional device;
- [for those currently using overnight therapy]: Considered by the site investigator to be at risk of an AE resulting from hypersomnolence the day after the overnight visit, such as a high-risk occupation including but not limited to a pilot or commercial driver;
- An employee, or family member of an employee, of a company that designs, sells, or manufactures sleep related products (including Philips).
Data sourced from ClinicalTrials.gov (NCT04671342). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.